|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 19, 2018 ) According to the new market research report “High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022", published by MarketsandMarkets™,The global high-content screening market is expected to reach USD 909.0 Million by 2022 from USD 557.1 Million in 2017, at a CAGR of 10.3%.
Get 10% Free Customization @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=42710391
The need for cost containment in pharma R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market.
High-content screening (HCS) is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. High-content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.
In 2016, the instruments segment accounted for the largest share in the HCS market. The large share of this segment is attributed to advanced automation techniques and high prices of HCS instruments. The cell imaging and analysis systems sub-segment accounted for the largest share of the HCS instruments market and is expected to further dominate the market by 2022.
Browse and in-depth TOC on “High Content Screening Market”
138 - Tables
42 - Figures
166 - Pages
For Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=42710391
Primary and Secondary Screening
The major users of HCS for primary and secondary screening are pharmaceutical and biotechnology companies and CROs involved in the drug discovery process. In recent years, the market has witnessed significant developments involving major players and prominent research institutes focusing on the use of HCS in screening applications. In secondary screening, HCS is used in qualitative assays to exclude the compounds with unintended modes of action.
Target Identification and Validation
Target identification and validation is the initial step in the drug discovery process. The benefits of high-content screening are especially relevant in drug discovery. Currently, late-stage failure during drug development can result in significant financial losses for companies. To eliminate this possibility, detailed insights are essential into how a drug or compound acts in a functional context on a cellular pathway. This results in more information and confidence in both hit selection as well as safety & efficacy, prior to lead candidate selection. Thus, target identification is a vital step in the drug discovery process.
The prominent players in the global high-content screening market are GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.). Product launches was the key growth strategy adopted by market players between 2014 and 2017. Companies also aim to differentiate themselves in the highly competitive global high-content screening market by expanding their product portfolios in accordance with industry trends and client needs.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/high-content-screening-market.asp
Visit Our Website: https://www.marketsandmarkets.com
MarketsandMarkets
Mr. Shelly Singh
1-888-600-6441
sales@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
